{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer+in+Normal+and+Malignant+Tumors&page=18", "query": { "condition": "Lung Cancer in Normal and Malignant Tumors", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 845, "total_pages": 85, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer+in+Normal+and+Malignant+Tumors&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lung+Cancer+in+Normal+and+Malignant+Tumors&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T06:31:52.205Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05479812", "title": "Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Solid Tumor", "Advanced Solid Tumor" ], "interventions": [ { "name": "WTX-124", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Werewolf Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 156, "start_date": "2022-08-15", "completion_date": "2026-04-22", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479812" }, { "nct_id": "NCT02357992", "title": "Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiotherapy (SABR)", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2010-04-05", "completion_date": "2021-09-17", "has_results": true, "last_update_posted_date": "2022-10-14", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02357992" }, { "nct_id": "NCT05888831", "title": "A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986449", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2023-06-06", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 4, "location_summary": "Los Angeles, California • New Haven, Connecticut • Hackensack, New Jersey + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Lake Success", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05888831" }, { "nct_id": "NCT03132922", "title": "MAGE-A4ᶜ¹º³²T for Multi-Tumor", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Urinary Bladder Cancer", "Melanoma", "Head and Neck Cancer", "Ovarian Cancer", "Non-Small Cell Lung Cancer", "Esophageal Cancer", "Gastric Cancer", "Synovial Sarcoma", "Myxoid Round Cell Liposarcoma", "Gastroesophageal Junction" ], "interventions": [ { "name": "Autologous genetically modified MAGE-A4ᶜ¹º³²T cells", "type": "GENETIC" }, { "name": "Autologous genetically modified MAGE-A4c1032T cells combined with low dose radiation", "type": "RADIATION" } ], "intervention_types": [ "GENETIC", "RADIATION" ], "sponsor": "USWM CT, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 71, "start_date": "2017-05-15", "completion_date": "2032-09", "has_results": true, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 10, "location_summary": "Miami, Florida • Tampa, Florida • St Louis, Missouri + 6 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03132922" }, { "nct_id": "NCT03517488", "title": "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma", "Breast Carcinoma", "Hepatocellular Carcinoma", "Urothelial Carcinoma", "Squamous Cell Carcinoma of the Head and Neck", "Renal Cell Carcinoma", "Colorectal Carcinoma", "Non-small Cell Lung Carcinoma", "Gastric or Gastroesophageal Junction Adenocarcinoma", "Endometrial Carcinoma", "Mesothelioma", "Neuroendocrine Carcinoma", "Cervical Cancer", "Small Cell Lung Carcinoma", "Squamous Cell Carcinoma of the Anus", "Castration-Resistant Prostate Carcinoma", "Nasopharyngeal Carcinoma", "Cholangiocarcinoma", "Basal Cell Carcinoma", "Ovarian Carcinoma", "Fallopian Tube Carcinoma", "Thymoma", "Thymic Carcinoma", "Squamous Cell Carcinoma of the Penis", "Vulvar Carcinoma", "Solid Tumors With Published Evidence of Anti-tumor Activity With Anti-PD1/PDL1 and/or Anti-CTLA4-directed Therapy", "Malignant Adnexal Neoplasms", "Non-squamous Cell Salivary Gland Carcinoma" ], "interventions": [ { "name": "XmAb20717", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2018-07-10", "completion_date": "2022-09-06", "has_results": false, "last_update_posted_date": "2022-12-01", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 17, "location_summary": "Los Angeles, California • San Diego, California • San Francisco, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03517488" }, { "nct_id": "NCT01341496", "title": "Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Melanoma", "Epithelial Malignancies", "Pleural Malignancy" ], "interventions": [ { "name": "Epigenetically Modified Autologous Tumor", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 41, "start_date": "2011-04-18", "completion_date": "2016-07-21", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01341496" }, { "nct_id": "NCT04514497", "title": "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Lung Small Cell Carcinoma", "Metastatic Malignant Solid Neoplasm", "Metastatic Neuroendocrine Carcinoma", "Metastatic Pancreatic Adenocarcinoma", "Stage III Lung Cancer AJCC v8", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Lung Small Cell Carcinoma", "Unresectable Malignant Solid Neoplasm", "Unresectable Neuroendocrine Carcinoma", "Unresectable Pancreatic Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Elimusertib", "type": "DRUG" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Topotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2021-10-20", "completion_date": "2027-03-04", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Orange, California • New Haven, Connecticut + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Trumbull", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04514497" }, { "nct_id": "NCT06956690", "title": "A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Non Small Cell Lung Cancer", "Breast Cancer" ], "interventions": [ { "name": "ENV-501", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Hummingbird Bioscience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2025-12-17", "completion_date": "2027-07", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 5, "location_summary": "La Jolla, California • Indianapolis, Indiana • Farmington Hills, Michigan + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Farmington Hills", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06956690" }, { "nct_id": "NCT07160335", "title": "A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-small Cell Lung Cancer", "Melanoma", "Renal Cell Carcinoma" ], "interventions": [ { "name": "HLX17", "type": "DRUG" }, { "name": "US-sourced Keytruda®", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shanghai Henlius Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 174, "start_date": "2025-09-26", "completion_date": "2028-03-27", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 12, "location_summary": "Glendale, California • Los Alamitos, California • Los Angeles, California + 8 more", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Bernardino", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07160335" }, { "nct_id": "NCT01557881", "title": "Positron Emission Tomography/Magnetic Resonance Imaging in Patients", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Colon Cancer", "Head and Neck Cancer", "Lung Cancer", "Lymphoma", "Malignant Neoplasm", "Melanoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "magnetic resonance imaging with positron emission tomography scanning", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 98, "start_date": "2012-02", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-10-14T06:31:52.205Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01557881" } ] }